Thrombin-mediated hepatocellular carcinoma cell migration: Cooperative action via proteinase-activated receptors 1 and 4
Proteinase‐activated receptor‐1 (PAR1), a thrombin receptor and the prototype of a newly discovered G‐protein‐coupled receptor subfamily, plays an important role in tumor development and progression. In this study, we documented the expression of the thrombin receptors PAR1, PAR3, and PAR4 in perman...
Saved in:
Published in | Journal of cellular physiology Vol. 211; no. 3; pp. 699 - 707 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.06.2007
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Proteinase‐activated receptor‐1 (PAR1), a thrombin receptor and the prototype of a newly discovered G‐protein‐coupled receptor subfamily, plays an important role in tumor development and progression. In this study, we documented the expression of the thrombin receptors PAR1, PAR3, and PAR4 in permanent hepatocellular carcinoma (HCC) cell lines and primary HCC cell cultures. Stimulation of HCC cells with thrombin and the PAR1‐selective activating peptide, TFLLRN‐NH2, increased transmembrane migration across a collagen barrier. This effect was blocked by the PAR1 antagonist SCH 79797, confirming that the PAR1 thrombin receptor subtype is involved in regulating hepatoma cell migration. In addition, the PAR4‐selective agonist, AYPGKF‐NH2, also stimulated HCC cell migration whilst the PAR4 antagonist, trans‐cinnamoyl‐YPGKF‐NH2, attenuated the effect of thrombin on HCC cell migration. PAR1‐ and PAR4‐triggered HCC cell migration was blocked by inhibiting a number of key mediators of signal transduction, including G proteins of the Gi/Go family, matrix metalloproteinases, ERK/MAPKinase, cyclic AMP‐dependent protein kinase, Src tyrosine kinase, and the EGF receptor kinase. Our data point to a cooperative PAR1/PAR4 signaling network that contributes to thrombin‐mediated tumor cell migration. We suggest that a combined inhibition of coagulation cascade serine proteinases, the two PARs and their complex signaling pathways may provide a new strategy for treating hepatocellular carcinoma. J. Cell. Physiol. 211: 699–707, 2007. © 2007 Wiley‐Liss, Inc. |
---|---|
AbstractList | Abstract
Proteinase‐activated receptor‐1 (PAR
1
), a thrombin receptor and the prototype of a newly discovered G‐protein‐coupled receptor subfamily, plays an important role in tumor development and progression. In this study, we documented the expression of the thrombin receptors PAR
1
, PAR
3
, and PAR
4
in permanent hepatocellular carcinoma (HCC) cell lines and primary HCC cell cultures. Stimulation of HCC cells with thrombin and the PAR
1
‐selective activating peptide, TFLLRN‐NH
2
, increased transmembrane migration across a collagen barrier. This effect was blocked by the PAR
1
antagonist SCH 79797, confirming that the PAR
1
thrombin receptor subtype is involved in regulating hepatoma cell migration. In addition, the PAR
4
‐selective agonist, AYPGKF‐NH
2
, also stimulated HCC cell migration whilst the PAR
4
antagonist, trans‐cinnamoyl‐YPGKF‐NH
2
, attenuated the effect of thrombin on HCC cell migration. PAR
1
‐ and PAR
4
‐triggered HCC cell migration was blocked by inhibiting a number of key mediators of signal transduction, including G proteins of the G
i
/G
o
family, matrix metalloproteinases, ERK/MAPKinase, cyclic AMP‐dependent protein kinase, Src tyrosine kinase, and the EGF receptor kinase. Our data point to a cooperative PAR
1
/PAR
4
signaling network that contributes to thrombin‐mediated tumor cell migration. We suggest that a combined inhibition of coagulation cascade serine proteinases, the two PARs and their complex signaling pathways may provide a new strategy for treating hepatocellular carcinoma. J. Cell. Physiol. 211: 699–707, 2007. © 2007 Wiley‐Liss, Inc. Proteinase-activated receptor-1 (PAR(1)), a thrombin receptor and the prototype of a newly discovered G-protein-coupled receptor subfamily, plays an important role in tumor development and progression. In this study, we documented the expression of the thrombin receptors PAR(1), PAR(3), and PAR(4) in permanent hepatocellular carcinoma (HCC) cell lines and primary HCC cell cultures. Stimulation of HCC cells with thrombin and the PAR(1)-selective activating peptide, TFLLRN-NH(2), increased transmembrane migration across a collagen barrier. This effect was blocked by the PAR(1) antagonist SCH 79797, confirming that the PAR(1) thrombin receptor subtype is involved in regulating hepatoma cell migration. In addition, the PAR(4)-selective agonist, AYPGKF-NH(2), also stimulated HCC cell migration whilst the PAR(4) antagonist, trans-cinnamoyl-YPGKF-NH(2), attenuated the effect of thrombin on HCC cell migration. PAR(1)- and PAR(4)-triggered HCC cell migration was blocked by inhibiting a number of key mediators of signal transduction, including G proteins of the G(i)/G(o) family, matrix metalloproteinases, ERK/MAPKinase, cyclic AMP-dependent protein kinase, Src tyrosine kinase, and the EGF receptor kinase. Our data point to a cooperative PAR(1)/PAR(4) signaling network that contributes to thrombin-mediated tumor cell migration. We suggest that a combined inhibition of coagulation cascade serine proteinases, the two PARs and their complex signaling pathways may provide a new strategy for treating hepatocellular carcinoma. Proteinase‐activated receptor‐1 (PAR1), a thrombin receptor and the prototype of a newly discovered G‐protein‐coupled receptor subfamily, plays an important role in tumor development and progression. In this study, we documented the expression of the thrombin receptors PAR1, PAR3, and PAR4 in permanent hepatocellular carcinoma (HCC) cell lines and primary HCC cell cultures. Stimulation of HCC cells with thrombin and the PAR1‐selective activating peptide, TFLLRN‐NH2, increased transmembrane migration across a collagen barrier. This effect was blocked by the PAR1 antagonist SCH 79797, confirming that the PAR1 thrombin receptor subtype is involved in regulating hepatoma cell migration. In addition, the PAR4‐selective agonist, AYPGKF‐NH2, also stimulated HCC cell migration whilst the PAR4 antagonist, trans‐cinnamoyl‐YPGKF‐NH2, attenuated the effect of thrombin on HCC cell migration. PAR1‐ and PAR4‐triggered HCC cell migration was blocked by inhibiting a number of key mediators of signal transduction, including G proteins of the Gi/Go family, matrix metalloproteinases, ERK/MAPKinase, cyclic AMP‐dependent protein kinase, Src tyrosine kinase, and the EGF receptor kinase. Our data point to a cooperative PAR1/PAR4 signaling network that contributes to thrombin‐mediated tumor cell migration. We suggest that a combined inhibition of coagulation cascade serine proteinases, the two PARs and their complex signaling pathways may provide a new strategy for treating hepatocellular carcinoma. J. Cell. Physiol. 211: 699–707, 2007. © 2007 Wiley‐Liss, Inc. |
Author | Hollenberg, Morley D. Hommann, Merten Biskup, Christoph Dittmar, Yves Hertel, Julia Pollrich, Kristin Rahn, Stephanie Westermann, Martin Kaufmann, Roland Henklein, Peter Settmacher, Utz |
Author_xml | – sequence: 1 givenname: Roland surname: Kaufmann fullname: Kaufmann, Roland email: roland.kaufmann@med.uni-jena.de organization: Department of General, Visceral and Vascular Surgery, Medical Faculty at the Friedrich Schiller University Jena, Jena, Germany – sequence: 2 givenname: Stephanie surname: Rahn fullname: Rahn, Stephanie organization: Department of General, Visceral and Vascular Surgery, Medical Faculty at the Friedrich Schiller University Jena, Jena, Germany – sequence: 3 givenname: Kristin surname: Pollrich fullname: Pollrich, Kristin organization: Department of General, Visceral and Vascular Surgery, Medical Faculty at the Friedrich Schiller University Jena, Jena, Germany – sequence: 4 givenname: Julia surname: Hertel fullname: Hertel, Julia organization: Department of General, Visceral and Vascular Surgery, Medical Faculty at the Friedrich Schiller University Jena, Jena, Germany – sequence: 5 givenname: Yves surname: Dittmar fullname: Dittmar, Yves organization: Department of General, Visceral and Vascular Surgery, Medical Faculty at the Friedrich Schiller University Jena, Jena, Germany – sequence: 6 givenname: Merten surname: Hommann fullname: Hommann, Merten organization: Department of General, Visceral and Vascular Surgery, Medical Faculty at the Friedrich Schiller University Jena, Jena, Germany – sequence: 7 givenname: Peter surname: Henklein fullname: Henklein, Peter organization: Institute of Biochemistry, Charité, Humboldt University of Berlin, Berlin, Germany – sequence: 8 givenname: Christoph surname: Biskup fullname: Biskup, Christoph organization: Institute of Physiology II, Medical Faculty at the Friedrich Schiller University Jena, Jena, Germany – sequence: 9 givenname: Martin surname: Westermann fullname: Westermann, Martin organization: Electron Microscopy Center, Medical Faculty at the Friedrich Schiller University Jena, Germany – sequence: 10 givenname: Morley D. surname: Hollenberg fullname: Hollenberg, Morley D. organization: Canadian Institutes of Health Research Proteinases and Inflammation Network, Endocrine-Diabetes, Smooth Muscle and Mucosal Inflammation Groups, Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Canada – sequence: 11 givenname: Utz surname: Settmacher fullname: Settmacher, Utz organization: Department of General, Visceral and Vascular Surgery, Medical Faculty at the Friedrich Schiller University Jena, Jena, Germany |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/17323377$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kM1u1DAURi3Uik4LC14AeYXEIq1_4njMDo1gAFUtEkUgNtaNfUNdkji1M0P79iSdga5YWf587tH1d0wO-tgjIS84O-WMibMbN5wKzoR-QhacGV2UlRIHZDG98cKokh-R45xvGGPGSPmUHHEthZRaL8jd1XWKXR36okMfYERPr3GAMTps200LiTpILvSxAzpHtAs_E4wh9m_oKsYB58sWKbg5o9sAdEhxxNBDxmJOtw_ShA6HMaZMOYXe0_IZOWygzfh8f56Qr-_fXa0-FOeX64-rt-eFK4XWhWfg0INUxjFeSe3ZktdgGsG9a5hTsMSmdLVWpnKmlkYYD6pkbqml9Bq8PCGvdt5prdsN5tF2Ic8_gR7jJlvNpORyKSbw9Q50KeacsLFDCh2ke8uZnWu2U832oeaJfbmXbuqpt0dy3-sEnO2A36HF-_-b7KfV57_KYjcR8oh3_yYg_bKVllrZbxdru66-fFc_SmWl_AMcvZoB |
CitedBy_id | crossref_primary_10_3390_cancers14143412 crossref_primary_10_2217_epi_2017_0101 crossref_primary_10_1245_s10434_010_1163_4 crossref_primary_10_1289_ehp_1306937 crossref_primary_10_1007_s00018_011_0678_6 crossref_primary_10_1093_abbs_gmu108 crossref_primary_10_1002_ijc_24070 crossref_primary_10_1007_s10735_010_9274_6 crossref_primary_10_1245_s10434_012_2338_y crossref_primary_10_3892_ol_2011_291 crossref_primary_10_7314_APJCP_2013_14_6_3793 crossref_primary_10_1186_1478_811X_11_86 crossref_primary_10_1007_s00432_010_0961_1 crossref_primary_10_1021_acsmedchemlett_8b00538 crossref_primary_10_1002_jcb_22608 crossref_primary_10_1016_j_biocel_2011_05_008 crossref_primary_10_1155_2015_840542 crossref_primary_10_1186_s12964_020_00552_7 crossref_primary_10_1002_ijc_29537 crossref_primary_10_1155_2015_437695 crossref_primary_10_33160_yam_2021_05_007 crossref_primary_10_1126_scisignal_2003813 crossref_primary_10_1096_fj_14_252551 crossref_primary_10_1111_j_1538_7836_2011_04447_x crossref_primary_10_1007_s00432_014_1863_4 crossref_primary_10_3892_ol_2018_9407 crossref_primary_10_1038_onc_2008_488 crossref_primary_10_1093_ije_dyu006 crossref_primary_10_1371_journal_pone_0122678 crossref_primary_10_1016_j_brainresrev_2007_08_002 crossref_primary_10_1517_13543776_2010_487864 crossref_primary_10_3748_wjg_v20_i34_11977 crossref_primary_10_1155_2018_4735752 crossref_primary_10_1002_JLB_3MR0120_390R crossref_primary_10_1111_j_1478_3231_2012_02865_x crossref_primary_10_1371_journal_pone_0094993 crossref_primary_10_1093_gigascience_giad117 crossref_primary_10_1016_j_pharmthera_2011_01_003 crossref_primary_10_1093_carcin_bgp153 |
Cites_doi | 10.1182/blood.V95.10.3133 10.1161/CIRCULATIONAHA.105.587758 10.1016/0092-8674(91)90261-V 10.1152/physrev.00028.2003 10.1038/47260 10.1038/nm0898-909 10.1002/(SICI)1097-0142(19971201)80:11<2068::AID-CNCR5>3.0.CO;2-T 10.1074/jbc.M513138200 10.1586/14779072.2.5.777 10.1016/0003-2697(76)90527-3 10.1038/35007085 10.1096/fj.02-0316com 10.1074/jbc.M312090200 10.1139/y01-013 10.1038/386502a0 10.1055/s-2003-40962 10.1016/0014-5793(91)81017-3 10.1124/pr.54.2.203 10.1074/jbc.M213091200 10.1073/pnas.0406682102 10.1182/blood.V92.10.3694 10.1126/science.6836310 10.1016/j.cell.2004.12.018 10.1210/er.2003-0025 10.1016/S0090-4295(02)01969-6 10.3322/canjclin.55.2.74 10.1097/00043426-200005000-00019 10.1016/S0002-9440(10)64675-5 10.1073/pnas.95.12.6642 10.1055/s-2005-871200 10.1002/hep.21196 10.1074/jbc.M007027200 10.1073/pnas.91.20.9208 10.1016/S0021-9258(18)43613-7 10.1158/1541-7786.395.2.7 10.1007/BF00132981 10.1097/00062752-199603050-00008 10.1055/s-0037-1616053 10.1038/sj.onc.1206453 10.1016/S0002-9440(10)64283-6 10.1038/sj.bjc.6690063 10.1182/blood-2004-03-1047 10.1016/S0006-2952(00)00460-3 |
ContentType | Journal Article |
Copyright | Copyright © 2007 Wiley‐Liss, Inc.‐Wiley‐Liss, Inc. |
Copyright_xml | – notice: Copyright © 2007 Wiley‐Liss, Inc.‐Wiley‐Liss, Inc. |
DBID | BSCLL CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1002/jcp.21027 |
DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Biology |
EISSN | 1097-4652 |
EndPage | 707 |
ExternalDocumentID | 10_1002_jcp_21027 17323377 JCP21027 ark_67375_WNG_G6SX5Z45_3 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Canadian Institutes of Health Research – fundername: Servier International Alliance Project – fundername: Proteinases and Inflammation (PAIN) Group – fundername: Interdisciplinary Center for Clinical Research (ICCR) Jena funderid: B 307‐04004 |
GroupedDBID | --- -DZ -~X .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 36B 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 9M8 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDPE ABEFU ABEML ABIJN ABJNI ABPPZ ABPVW ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AIAGR AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AUFTA AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BMXJE BNHUX BQCPF BROTX BRXPI BSCLL BY8 CS3 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRSTM DU5 EBD EBS EJD EMB EMOBN F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA H.T H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ H~9 IH2 IX1 J0M JPC KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M56 MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MVM MXFUL MXSTM N04 N05 N9A NEJ NF~ NNB O66 O9- OHT OIG P2P P2W P2X P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO ROL RWI RWR RX1 RYL S10 SAMSI SUPJJ SV3 TN5 TWZ UB1 UPT V2E V8K VQP W8V W99 WBKPD WH7 WIB WIH WIK WJL WNSPC WOHZO WQJ WRC WXSBR WYB WYISQ X7M XG1 XJT XOL XPP XSW XV2 Y6R YQT YZZ ZGI ZXP ZZTAW ~IA ~WT AETEA G8K CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c4277-d0aceda359c01637d081ba9f21dcf0c5a8ef4cb7596c9b3929da540c8733d7ad3 |
IEDL.DBID | DR2 |
ISSN | 0021-9541 |
IngestDate | Sat Aug 17 04:17:07 EDT 2024 Thu Sep 26 17:27:38 EDT 2024 Sat Sep 28 07:56:34 EDT 2024 Sat Aug 24 01:01:07 EDT 2024 Wed Oct 30 09:50:44 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4277-d0aceda359c01637d081ba9f21dcf0c5a8ef4cb7596c9b3929da540c8733d7ad3 |
Notes | Proteinases and Inflammation (PAIN) Group ark:/67375/WNG-G6SX5Z45-3 Servier International Alliance Project Interdisciplinary Center for Clinical Research (ICCR) Jena - No. B 307-04004 Canadian Institutes of Health Research istex:608CBE0A0B702DDF8E5599C369DDC6BBA75DE41A ArticleID:JCP21027 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 17323377 |
PQID | 70331382 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_70331382 crossref_primary_10_1002_jcp_21027 pubmed_primary_17323377 wiley_primary_10_1002_jcp_21027_JCP21027 istex_primary_ark_67375_WNG_G6SX5Z45_3 |
PublicationCentury | 2000 |
PublicationDate | June 2007 |
PublicationDateYYYYMMDD | 2007-06-01 |
PublicationDate_xml | – month: 06 year: 2007 text: June 2007 |
PublicationDecade | 2000 |
PublicationPlace | Hoboken |
PublicationPlace_xml | – name: Hoboken – name: United States |
PublicationTitle | Journal of cellular physiology |
PublicationTitleAlternate | J. Cell. Physiol |
PublicationYear | 2007 |
Publisher | Wiley Subscription Services, Inc., A Wiley Company |
Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company |
References | Nystedt S, Emilsson K, Wahlestedt C, Sundelin J. 1994. Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci USA 91: 9208-9212. Kamath L, Meydani A, Foss F, Kuliopulos A. 2001. Signaling form protease-activated receptor-1 inhibits migration and invasion of breast cancer cells. Cancer Res 61: 5933-5940. Ruf W, Mueller BM. 1996. Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol 3: 379-384. Fischer EG, Ruf W, Mueller BM. 1995. Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Res 55: 1629-1632. Zacharski LR, Hommann M, Kaufmann R. 2004. Rationale for clinical trials of coagulation: Reactive drugs in hepatocellular carcinoma. Expert Rev Cardiovasc Ther 2: 777-784. Palumbo JS, Degen JD. 2000. Hemostatic factors in tumor biology. J Pediatr Hematol Oncol 22: 281-287. Oikonomopoulou K, Hansen KK, Saifeddine M, Tea I, Blaber M, Blaber SI, Scarisbrick I, Andrade-Gordon P, Cottrell GS, Bunnett NW, Diamandis EP, Hollenberg MD. 2006. Proteinase-activated receptors, targets for Kallikrein signaling. J Biol Chem 281: 32095-32112. Hu L, Lee M, Campbell W, Perez-Soler R, Karpatkin S. 2002. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 104: 2746-2751. Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, Luger TA, Hollenberg MD. 2005. Proteinase-activated receptors: Transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 26: 1-43. Lynn M, Nierodzik ML, Kajumo LR, Karpatkin S. 1992. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res 52: 3267-3272. Sabri A, Guo J, Elouardighi H, Darrow AL, Andrade-Gordon P, Steinberg SF. 2003. Mechanisms of protease-activated receptor-4 actions in cardiomyocytes. Role of Src tyrosine kinase. J Biol Chem 278: 11714-11720. Chay CH, Cooper CR, Gendernalik JD, Dhanasekaran SM, Chinnaiyan AM, Rubin MA, Schmaier AH, Pienta KJ. 2002. A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology 60: 760-765. Rasmussen UB, Vouret-Craviari V, Jallat S, Schlesinger S, Page G, Pavirani A, Lecocq JP, Pouyssegur J, Obberghen-Schilling JE. 1991. cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca2+ mobilization. FEBS Lett 288: 123-128. Even-Ram SC, Maoz M, Pokroy E, Reich R, Katz BZ, Gutwein P, Altevogt P, Bar-Shavit R. 2001. Tumor cell invasion is promoted by activation of protease-activated receptor-1 in cooperation with αvß5 integrin. J Biol Chem 276: 10952-10962. Bradford MM. 1976. A refined and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. 2000. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 404: 609-613. Henrikson KP, Salazar SL, Fenton JW, Pentecost BT. 1999. Role of thrombin receptor in breast cancer invasiveness. Br J Cancer 179: 401-406. Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M. 2003. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induce cell proliferation and motility in human colon cancer cells. Am J Pathol 162: 1503-1513. Branda M, Wands JR. 2006. Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology 43: 891-902. Ahn HS, Foster C, Boykow G, Stamford A, Manna M, Graziano M. 2000. Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1, 3-diamine hydrochloride (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem Pharmacol 60: 1425-1434. Nierodzik ML, Chen K, Takeshita K, Li JJ, Huang YQ, Feng XS, D'Andrea MR, Andrade-Gordon P, Karpatkin S. 1998. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 92: 3694-3700. Cottrell GS, Amadesi S, Grady EF, Bunnett NW. 2004. Trypsin IV, a novel agonist of protease-activated receptors 2 and 4. J Biol Chem 279: 13532-13539. Bar-Shavit R, Mudd M, Wilner G, Mann K, Fenton JW, II. 1983. Monocyte chemotaxis: Stimulation by specific exosite region in thrombin. Science 220: 728-731. Ossovskaya VS, Bunnett NW. 2004. Protease-activated receptors: Contribution to physiology and disease. Physiol Rev 84: 579-621. Tellez C, Bar-Eli M. 2003. Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene 22: 3130-3137. Shi X, Gangadharan B, Brass LF, Ruf W, Mueller BM. 2004. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2: 395-402. Kaufmann R, Schafberg H, Rudroff C, Nowak G. 1997. Thrombin receptor activation results in calcium signalling and PKC-dependent Stimulation of DNA Synthesis in Hep-2 laryngeal carcinoma cells. Cancer 80: 2068-2074. Roberts LR, Gores GJ. 2005. Hepatocellular carcinoma: Molecular pathways and new therapeutic targets. Sem Liv Dis 25: 212-225. Zain J, Huang YQ, Feng X, Nierodzik ML, Li JJ, Karpatkin S. 2000. Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. Blood 95: 3133-3138. Parkin DM, Bray F, Ferlay J, Pisani P. 2005. Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108. Zacharski LR. 2003. Malignancy as a solid phase coagulopathy: Implications for the etiology, pathogenesis and treatment of cancer. Semin Thrombos Hemostas 29: 239-246. Hollenberg MD, Saifeddine M. 2001. Proteinase-activated receptor 4 (PAR4): Activation and inhibition of rat platelet aggregation by PAR4-derived peptides. Can J Physiol Pharmacol 79: 439-442. Hangan D, Uniyal S, Morris VL, von Ballestrem C, Uniyal S, Chan BM. 1996. Integrin VLA-2 (α2ß1) function in postextravasation movement of human rhabdomyosarcoma RD cells in the liver. Cancer Res 56: 3142-3147. Xu WF, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, Gilbert T, Davie EW, Foster DC. 1998. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci USA 95: 6642-6646. Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, Reich R, Vlodavsky I, Bar-Shavit R. 1998. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 4: 909-914. Kaufmann R, Junker U, Nuske K, Westermann M, Henklein P, Scheele J, Junker K. 2002. PAR-1- and PAR-3-type thrombin receptor expression in primary cultures of human renal cell carcinoma cells. Int J Oncol 20: 177-180. Kawabata A, Saifeddine M, Al-Ani B, Leblond L, Hollenberg MD. 1999. Evaluation of proteinase-activated receptor-1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: Activation of PAR2 by PAR1-targeted ligands. J Pharmacol Exp Ther 288: 358-370. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. 1999. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402: 884-888. Ma L, Perini R, McKnight W, Dicay M, Klein A, Hollenberg MD, Wallace JL. 2005. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci USA 102: 216-220. Bergmann S, Junker K, Henklein P, Hollenberg MD, Settmacher U, Kaufmann R. 2006. PAR-type thrombin receptors in renal carcinoma cells: PAR1-mediated EGFR activation promotes cell migration. Oncol Rep 15: 889-893. Glenn K, Carney D, Fenton J, Cunningham D. 1980. Thrombin active-site regions required for fibroblast receptor binding and initiation of cell division. J Biol Chem 255: 6609-6616. Galardy RE, Grobelny D, Foellmer HG, Fernandez LA. 1994. Inhibition of angiogenesis by the matrix metalloprotease inhibitor N-[2R-2-(hydroxamidocarbonymethyl)-4-methylpentanoyl)]-L-tryptophan methylamide. Cancer Res 54: 4715-4718. Bromberg ME, Bailly MA, Konigsberg WH. 2001. Role of protease activated receptor 1 in tumor cell metastasis promoted by tissue factor. Thromb Haemost 86: 1210-1214. Yin YJ, Salah Z, Maoz M, Ram SC, Ochayon S, Neufeld G, Katzav S, Bar-Shavit R. 2003. Oncogenic transformation induces tumor angiogenesis: A role for PAR1 activation. FASEB J 17: 163-174. Vu TK, Hung DT, Wheaton VI, Coughlin SR. 1991. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64: 1057-1068. D'Andrea MR, Derian CK, Santulli RJ, Andrade-Gordon P. 2001. Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. Am J Pathol 158: 2031-2041. Hollenberg MD, Compton SJ. 2002. International Union of Pharmacology. XVIII. Proteinase-activated receptors. Pharmacol Rev 54: 203-217. Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR. 1997. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 386: 502-506. Wojtukiewicz MZ, Tang DG, Ben-Josef E, Renaud C, Walz DA, Honn KV. 1995. Solid tumor cells express functional "tethered ligand" thrombin receptor. Cancer Res 55: 698-704. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. 2005. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120: 3303-3313. Leger AJ, Jacques SL, Badar J, Kaneider NC, Derian CK, Andrade-Gordon P, Covic L, Kuliopulos A. 2006. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 113: 1244-1254. 1997; 80 2002; 54 2000; 95 2003; 17 2002; 60 2004; 2 1999; 288 2005; 26 2003; 278 1999; 402 1980; 255 2001; 86 1992; 52 2005; 25 2001; 61 1983; 220 2005; 102 1976; 72 2000; 404 1997; 386 2003; 162 2002; 104 2000; 60 1999; 179 1998; 92 1981 2006; 281 1998; 95 1996; 3 2004; 84 2000; 22 1995; 55 2006; 15 1996; 56 2006; 113 2001; 276 2004; 279 1991; 288 2005; 120 2002; 20 2006; 43 1991; 64 2003; 29 1994; 91 2001; 79 1998; 4 2005; 55 2001; 158 1994; 54 2003; 22 e_1_2_6_51_1 e_1_2_6_53_1 e_1_2_6_32_1 Kawabata A (e_1_2_6_28_1) 1999; 288 e_1_2_6_19_1 Galardy RE (e_1_2_6_17_1) 1994; 54 Glenn K (e_1_2_6_18_1) 1980; 255 e_1_2_6_13_1 e_1_2_6_36_1 e_1_2_6_11_1 e_1_2_6_34_1 e_1_2_6_15_1 e_1_2_6_38_1 e_1_2_6_43_1 e_1_2_6_20_1 Bromberg ME (e_1_2_6_9_1) 2001; 86 e_1_2_6_41_1 Lynn M (e_1_2_6_30_1) 1992; 52 e_1_2_6_7_1 e_1_2_6_24_1 e_1_2_6_49_1 e_1_2_6_3_1 e_1_2_6_22_1 e_1_2_6_45_1 e_1_2_6_26_1 e_1_2_6_47_1 e_1_2_6_52_1 Fischer EG (e_1_2_6_16_1) 1995; 55 e_1_2_6_10_1 Kamath L (e_1_2_6_25_1) 2001; 61 e_1_2_6_31_1 e_1_2_6_50_1 Bergmann S (e_1_2_6_4_1) 2006; 15 e_1_2_6_14_1 e_1_2_6_35_1 e_1_2_6_12_1 e_1_2_6_33_1 Kaufmann R (e_1_2_6_27_1) 2002; 20 Wojtukiewicz MZ (e_1_2_6_48_1) 1995; 55 e_1_2_6_39_1 e_1_2_6_37_1 e_1_2_6_42_1 e_1_2_6_21_1 e_1_2_6_40_1 e_1_2_6_8_1 e_1_2_6_6_1 e_1_2_6_23_1 e_1_2_6_2_1 e_1_2_6_29_1 e_1_2_6_44_1 Berndt M (e_1_2_6_5_1) 1981 e_1_2_6_46_1 |
References_xml | – volume: 158 start-page: 2031 year: 2001 end-page: 2041 article-title: Differential expression of protease‐activated receptors‐1 and ‐2 in stromal fibroblasts of normal, benign, and malignant human tissues publication-title: Am J Pathol – volume: 2 start-page: 395 year: 2004 end-page: 402 article-title: Protease‐activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis publication-title: Mol Cancer Res – volume: 288 start-page: 358 year: 1999 end-page: 370 article-title: Evaluation of proteinase‐activated receptor‐1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: Activation of PAR2 by PAR1‐targeted ligands publication-title: J Pharmacol Exp Ther – volume: 26 start-page: 1 year: 2005 end-page: 43 article-title: Proteinase‐activated receptors: Transducers of proteinase‐mediated signaling in inflammation and immune response publication-title: Endocr Rev – volume: 56 start-page: 3142 year: 1996 end-page: 3147 article-title: Integrin VLA‐2 (α ß ) function in postextravasation movement of human rhabdomyosarcoma RD cells in the liver publication-title: Cancer Res – volume: 55 start-page: 74 year: 2005 end-page: 108 article-title: Global cancer statistics, 2002 publication-title: CA Cancer J Clin – volume: 29 start-page: 239 year: 2003 end-page: 246 article-title: Malignancy as a solid phase coagulopathy: Implications for the etiology, pathogenesis and treatment of cancer publication-title: Semin Thrombos Hemostas – volume: 281 start-page: 32095 year: 2006 end-page: 32112 article-title: Proteinase‐activated receptors, targets for Kallikrein signaling publication-title: J Biol Chem – volume: 278 start-page: 11714 year: 2003 end-page: 11720 article-title: Mechanisms of protease‐activated receptor‐4 actions in cardiomyocytes. Role of Src tyrosine kinase publication-title: J Biol Chem – volume: 86 start-page: 1210 year: 2001 end-page: 1214 article-title: Role of protease activated receptor 1 in tumor cell metastasis promoted by tissue factor publication-title: Thromb Haemost – volume: 84 start-page: 579 year: 2004 end-page: 621 article-title: Protease‐activated receptors: Contribution to physiology and disease publication-title: Physiol Rev – volume: 55 start-page: 1629 year: 1995 end-page: 1632 article-title: Tissue factor‐initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells publication-title: Cancer Res – volume: 102 start-page: 216 year: 2005 end-page: 220 article-title: Proteinase‐activated receptors 1 and 4 counter‐regulate endostatin and VEGF release from human platelets publication-title: Proc Natl Acad Sci USA – volume: 22 start-page: 3130 year: 2003 end-page: 3137 article-title: Role and regulation of the thrombin receptor (PAR‐1) in human melanoma publication-title: Oncogene – volume: 60 start-page: 1425 year: 2000 end-page: 1434 article-title: Inhibition of cellular action of thrombin by N3‐cyclopropyl‐7‐[[4‐(1‐methylethyl)phenyl]methyl]‐7H‐pyrrolo[3, 2‐f]quinazoline‐1, 3‐diamine hydrochloride (SCH 79797), a nonpeptide thrombin receptor antagonist publication-title: Biochem Pharmacol – volume: 54 start-page: 203 year: 2002 end-page: 217 article-title: International Union of Pharmacology. XVIII. Proteinase‐activated receptors publication-title: Pharmacol Rev – volume: 220 start-page: 728 year: 1983 end-page: 731 article-title: Monocyte chemotaxis: Stimulation by specific exosite region in thrombin publication-title: Science – volume: 79 start-page: 439 year: 2001 end-page: 442 article-title: Proteinase‐activated receptor 4 (PAR4): Activation and inhibition of rat platelet aggregation by PAR4‐derived peptides publication-title: Can J Physiol Pharmacol – volume: 120 start-page: 3303 year: 2005 end-page: 3313 article-title: PAR1 is a matrix metalloprotease‐1 receptor that promotes invasion and tumorigenesis of breast cancer cells publication-title: Cell – volume: 404 start-page: 609 year: 2000 end-page: 613 article-title: PAR3 is a cofactor for PAR4 activation by thrombin publication-title: Nature – volume: 17 start-page: 163 year: 2003 end-page: 174 article-title: Oncogenic transformation induces tumor angiogenesis: A role for PAR1 activation publication-title: FASEB J – volume: 54 start-page: 4715 year: 1994 end-page: 4718 article-title: Inhibition of angiogenesis by the matrix metalloprotease inhibitor N‐[2R‐2‐(hydroxamidocarbonymethyl)‐4‐methylpentanoyl)]‐L‐tryptophan methylamide publication-title: Cancer Res – volume: 402 start-page: 884 year: 1999 end-page: 888 article-title: EGF receptor transactivation by G‐protein‐coupled receptors requires metalloproteinase cleavage of proHB‐EGF publication-title: Nature – volume: 55 start-page: 698 year: 1995 end-page: 704 article-title: Solid tumor cells express functional “tethered ligand” thrombin receptor publication-title: Cancer Res – volume: 20 start-page: 177 year: 2002 end-page: 180 article-title: PAR‐1‐ and PAR‐3‐type thrombin receptor expression in primary cultures of human renal cell carcinoma cells publication-title: Int J Oncol – volume: 52 start-page: 3267 year: 1992 end-page: 3272 article-title: Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo publication-title: Cancer Res – volume: 15 start-page: 889 year: 2006 end-page: 893 article-title: PAR‐type thrombin receptors in renal carcinoma cells: PAR ‐mediated EGFR activation promotes cell migration publication-title: Oncol Rep – volume: 61 start-page: 5933 year: 2001 end-page: 5940 article-title: Signaling form protease‐activated receptor‐1 inhibits migration and invasion of breast cancer cells publication-title: Cancer Res – volume: 113 start-page: 1244 year: 2006 end-page: 1254 article-title: Blocking the protease‐activated receptor 1‐4 heterodimer in platelet‐mediated thrombosis publication-title: Circulation – volume: 179 start-page: 401 year: 1999 end-page: 406 article-title: Role of thrombin receptor in breast cancer invasiveness publication-title: Br J Cancer – volume: 92 start-page: 3694 year: 1998 end-page: 3700 article-title: Protease‐activated receptor 1 (PAR‐1) is required and rate‐limiting for thrombin‐enhanced experimental pulmonary metastasis publication-title: Blood – volume: 276 start-page: 10952 year: 2001 end-page: 10962 article-title: Tumor cell invasion is promoted by activation of protease‐activated receptor‐1 in cooperation with α ß integrin publication-title: J Biol Chem – volume: 255 start-page: 6609 year: 1980 end-page: 6616 article-title: Thrombin active‐site regions required for fibroblast receptor binding and initiation of cell division publication-title: J Biol Chem – volume: 2 start-page: 777 year: 2004 end-page: 784 article-title: Rationale for clinical trials of coagulation: Reactive drugs in hepatocellular carcinoma publication-title: Expert Rev Cardiovasc Ther – volume: 80 start-page: 2068 year: 1997 end-page: 2074 article-title: Thrombin receptor activation results in calcium signalling and PKC‐dependent Stimulation of DNA Synthesis in Hep‐2 laryngeal carcinoma cells publication-title: Cancer – volume: 43 start-page: 891 year: 2006 end-page: 902 article-title: Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma publication-title: Hepatology – volume: 162 start-page: 1503 year: 2003 end-page: 1513 article-title: Aberrant expression and activation of the thrombin receptor protease‐activated receptor‐1 induce cell proliferation and motility in human colon cancer cells publication-title: Am J Pathol – volume: 104 start-page: 2746 year: 2002 end-page: 2751 article-title: Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis publication-title: Blood – volume: 25 start-page: 212 year: 2005 end-page: 225 article-title: Hepatocellular carcinoma: Molecular pathways and new therapeutic targets publication-title: Sem Liv Dis – volume: 95 start-page: 3133 year: 2000 end-page: 3138 article-title: Concentration‐dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells publication-title: Blood – volume: 64 start-page: 1057 year: 1991 end-page: 1068 article-title: Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation publication-title: Cell – volume: 60 start-page: 760 year: 2002 end-page: 765 article-title: A functional thrombin receptor (PAR1) is expressed on bone‐derived prostate cancer cell lines publication-title: Urology – start-page: 43 year: 1981 end-page: 47 – volume: 279 start-page: 13532 year: 2004 end-page: 13539 article-title: Trypsin IV, a novel agonist of protease‐activated receptors 2 and 4 publication-title: J Biol Chem – volume: 72 start-page: 248 year: 1976 end-page: 254 article-title: A refined and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein‐dye binding publication-title: Anal Biochem – volume: 288 start-page: 123 year: 1991 end-page: 128 article-title: cDNA cloning and expression of a hamster alpha‐thrombin receptor coupled to Ca mobilization publication-title: FEBS Lett – volume: 386 start-page: 502 year: 1997 end-page: 506 article-title: Protease‐activated receptor 3 is a second thrombin receptor in humans publication-title: Nature – volume: 4 start-page: 909 year: 1998 end-page: 914 article-title: Thrombin receptor overexpression in malignant and physiological invasion processes publication-title: Nat Med – volume: 95 start-page: 6642 year: 1998 end-page: 6646 article-title: Cloning and characterization of human protease‐activated receptor 4 publication-title: Proc Natl Acad Sci USA – volume: 22 start-page: 281 year: 2000 end-page: 287 article-title: Hemostatic factors in tumor biology publication-title: J Pediatr Hematol Oncol – volume: 91 start-page: 9208 year: 1994 end-page: 9212 article-title: Molecular cloning of a potential proteinase activated receptor publication-title: Proc Natl Acad Sci USA – volume: 3 start-page: 379 year: 1996 end-page: 384 article-title: Tissue factor in cancer angiogenesis and metastasis publication-title: Curr Opin Hematol – ident: e_1_2_6_53_1 doi: 10.1182/blood.V95.10.3133 – ident: e_1_2_6_29_1 doi: 10.1161/CIRCULATIONAHA.105.587758 – ident: e_1_2_6_47_1 doi: 10.1016/0092-8674(91)90261-V – ident: e_1_2_6_36_1 doi: 10.1152/physrev.00028.2003 – start-page: 43 volume-title: Platelets in biology and pathology year: 1981 ident: e_1_2_6_5_1 contributor: fullname: Berndt M – ident: e_1_2_6_39_1 doi: 10.1038/47260 – volume: 20 start-page: 177 year: 2002 ident: e_1_2_6_27_1 article-title: PAR‐1‐ and PAR‐3‐type thrombin receptor expression in primary cultures of human renal cell carcinoma cells publication-title: Int J Oncol contributor: fullname: Kaufmann R – ident: e_1_2_6_14_1 doi: 10.1038/nm0898-909 – ident: e_1_2_6_26_1 doi: 10.1002/(SICI)1097-0142(19971201)80:11<2068::AID-CNCR5>3.0.CO;2-T – ident: e_1_2_6_35_1 doi: 10.1074/jbc.M513138200 – ident: e_1_2_6_52_1 doi: 10.1586/14779072.2.5.777 – ident: e_1_2_6_7_1 doi: 10.1016/0003-2697(76)90527-3 – ident: e_1_2_6_32_1 doi: 10.1038/35007085 – ident: e_1_2_6_50_1 doi: 10.1096/fj.02-0316com – ident: e_1_2_6_11_1 doi: 10.1074/jbc.M312090200 – ident: e_1_2_6_22_1 doi: 10.1139/y01-013 – ident: e_1_2_6_24_1 doi: 10.1038/386502a0 – ident: e_1_2_6_51_1 doi: 10.1055/s-2003-40962 – volume: 55 start-page: 1629 year: 1995 ident: e_1_2_6_16_1 article-title: Tissue factor‐initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells publication-title: Cancer Res contributor: fullname: Fischer EG – ident: e_1_2_6_40_1 doi: 10.1016/0014-5793(91)81017-3 – ident: e_1_2_6_21_1 doi: 10.1124/pr.54.2.203 – ident: e_1_2_6_43_1 doi: 10.1074/jbc.M213091200 – ident: e_1_2_6_31_1 doi: 10.1073/pnas.0406682102 – volume: 55 start-page: 698 year: 1995 ident: e_1_2_6_48_1 article-title: Solid tumor cells express functional “tethered ligand” thrombin receptor publication-title: Cancer Res contributor: fullname: Wojtukiewicz MZ – volume: 54 start-page: 4715 year: 1994 ident: e_1_2_6_17_1 article-title: Inhibition of angiogenesis by the matrix metalloprotease inhibitor N‐[2R‐2‐(hydroxamidocarbonymethyl)‐4‐methylpentanoyl)]‐L‐tryptophan methylamide publication-title: Cancer Res contributor: fullname: Galardy RE – ident: e_1_2_6_33_1 doi: 10.1182/blood.V92.10.3694 – ident: e_1_2_6_3_1 doi: 10.1126/science.6836310 – ident: e_1_2_6_6_1 doi: 10.1016/j.cell.2004.12.018 – ident: e_1_2_6_45_1 doi: 10.1210/er.2003-0025 – ident: e_1_2_6_10_1 doi: 10.1016/S0090-4295(02)01969-6 – ident: e_1_2_6_38_1 doi: 10.3322/canjclin.55.2.74 – volume: 15 start-page: 889 year: 2006 ident: e_1_2_6_4_1 article-title: PAR‐type thrombin receptors in renal carcinoma cells: PAR1‐mediated EGFR activation promotes cell migration publication-title: Oncol Rep contributor: fullname: Bergmann S – ident: e_1_2_6_37_1 doi: 10.1097/00043426-200005000-00019 – ident: e_1_2_6_12_1 doi: 10.1016/S0002-9440(10)64675-5 – ident: e_1_2_6_49_1 doi: 10.1073/pnas.95.12.6642 – ident: e_1_2_6_41_1 doi: 10.1055/s-2005-871200 – ident: e_1_2_6_8_1 doi: 10.1002/hep.21196 – ident: e_1_2_6_15_1 doi: 10.1074/jbc.M007027200 – volume: 288 start-page: 358 year: 1999 ident: e_1_2_6_28_1 article-title: Evaluation of proteinase‐activated receptor‐1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: Activation of PAR2 by PAR1‐targeted ligands publication-title: J Pharmacol Exp Ther contributor: fullname: Kawabata A – ident: e_1_2_6_34_1 doi: 10.1073/pnas.91.20.9208 – volume: 255 start-page: 6609 year: 1980 ident: e_1_2_6_18_1 article-title: Thrombin active‐site regions required for fibroblast receptor binding and initiation of cell division publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)43613-7 contributor: fullname: Glenn K – ident: e_1_2_6_44_1 doi: 10.1158/1541-7786.395.2.7 – ident: e_1_2_6_19_1 doi: 10.1007/BF00132981 – ident: e_1_2_6_42_1 doi: 10.1097/00062752-199603050-00008 – volume: 86 start-page: 1210 year: 2001 ident: e_1_2_6_9_1 article-title: Role of protease activated receptor 1 in tumor cell metastasis promoted by tissue factor publication-title: Thromb Haemost doi: 10.1055/s-0037-1616053 contributor: fullname: Bromberg ME – ident: e_1_2_6_46_1 doi: 10.1038/sj.onc.1206453 – ident: e_1_2_6_13_1 doi: 10.1016/S0002-9440(10)64283-6 – ident: e_1_2_6_20_1 doi: 10.1038/sj.bjc.6690063 – volume: 52 start-page: 3267 year: 1992 ident: e_1_2_6_30_1 article-title: Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo publication-title: Cancer Res contributor: fullname: Lynn M – volume: 61 start-page: 5933 year: 2001 ident: e_1_2_6_25_1 article-title: Signaling form protease‐activated receptor‐1 inhibits migration and invasion of breast cancer cells publication-title: Cancer Res contributor: fullname: Kamath L – ident: e_1_2_6_23_1 doi: 10.1182/blood-2004-03-1047 – ident: e_1_2_6_2_1 doi: 10.1016/S0006-2952(00)00460-3 |
SSID | ssj0009933 |
Score | 2.1513476 |
Snippet | Proteinase‐activated receptor‐1 (PAR1), a thrombin receptor and the prototype of a newly discovered G‐protein‐coupled receptor subfamily, plays an important... Proteinase-activated receptor-1 (PAR(1)), a thrombin receptor and the prototype of a newly discovered G-protein-coupled receptor subfamily, plays an important... Abstract Proteinase‐activated receptor‐1 (PAR 1 ), a thrombin receptor and the prototype of a newly discovered G‐protein‐coupled receptor subfamily, plays an... |
SourceID | proquest crossref pubmed wiley istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 699 |
SubjectTerms | Calcium - metabolism Carcinoma, Hepatocellular - metabolism Carcinoma, Hepatocellular - pathology Cell Line, Tumor Cell Movement - drug effects Cell Movement - physiology Cyclic AMP-Dependent Protein Kinases - antagonists & inhibitors Cyclic AMP-Dependent Protein Kinases - metabolism Enzyme Inhibitors - pharmacology GTP-Binding Protein alpha Subunits, Gi-Go - metabolism Hemostatics - pharmacology Humans Liver Neoplasms - metabolism Liver Neoplasms - pathology MAP Kinase Signaling System - drug effects MAP Kinase Signaling System - physiology Matrix Metalloproteinases - metabolism Mitogen-Activated Protein Kinase 1 - antagonists & inhibitors Mitogen-Activated Protein Kinase 1 - metabolism Mitogen-Activated Protein Kinase 3 - antagonists & inhibitors Mitogen-Activated Protein Kinase 3 - metabolism Phosphorylation Protein Kinase C - antagonists & inhibitors Protein Kinase C - metabolism Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - metabolism Receptor, PAR-1 - genetics Receptor, PAR-1 - metabolism Receptors, Thrombin - genetics Receptors, Thrombin - metabolism Signal Transduction - drug effects Signal Transduction - physiology src-Family Kinases - antagonists & inhibitors src-Family Kinases - metabolism Thrombin - pharmacology |
Title | Thrombin-mediated hepatocellular carcinoma cell migration: Cooperative action via proteinase-activated receptors 1 and 4 |
URI | https://api.istex.fr/ark:/67375/WNG-G6SX5Z45-3/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcp.21027 https://www.ncbi.nlm.nih.gov/pubmed/17323377 https://search.proquest.com/docview/70331382 |
Volume | 211 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1faxQxEB9KpeCLra3as2qDSPFlr7ubZHOrT-X6j4JFtMVDhJBNsu1Zbve43hVb-uBH8DP6SZwkt3dUFMS3Jewm2WQy80sy8xuAV1kqUm6ojgprVMSEQD1IYxNZzkRJmS6Vz9bw7jg7PGVHPd5bgLdNLEzgh5gduLmV4fW1W-CquNyek4Z-1cO226-4SPKECufOtfthTh2VT9PIexcEzpKGVShOt2df3rFF99ywfvsT0LyLW73h2V-GL02Xg7_JRXsyLtr65jc2x__8pxV4MAWkZCdI0ENYsNUqrO1UuBkfXJMt4l1E_dn7KiyFzJXXa3B7cj6qB7ir_vn9hw8-QeBKztG0jWt3FeB8W4l2aYqqeqCIKyKD_lmQtjekW9dDGyjHSQisIFd9RTxnRL9Cu4q1uvIrXy3qZDt0SYFIQlRlCHsEp_t7J93DaJrIIdLMXRGbWGkUBcpzjQiTCoM4pFB5mSZGl7HmqmNLpgvB80znhUNsRiGS1B1BqRHK0MewWNWVXQfSQfGJS0Wzjs6ZKm1hVIoaGicYpQ6LWvCymVI5DHwdMjAzpxJHV_rRbcGWn-zZG2p04RzcBJefjg_kQfaxxz8zLmkLNhtpkLjs3GipytaTS4mKkjr6xhY8CUIyb03QlFKBjbz2U_33bsij7nv_8PTfX92A-43HYpw8g8XxaGKfIywaFy-8_P8CgesL8Q |
link.rule.ids | 315,783,787,1378,27936,27937,46306,46730 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFD4amxC8cNm4lNsshCZe0qWxHTeIl6mwlbFVCDqtQkKWYzusTE2q0k4M8cBP4DfySzi2m1ZDICHeIiuxneNzjj_bx98BeJImIuGG6ii3RkVMCPSDNDaR5UwUlOlC-WwNh720e8T2B3ywAs_ruzCBH2Kx4eYsw_trZ-BuQ3p7yRr6SY-bbsEiLsEamjt1iRtevF2SR2XzRPI-CIGzVs0rFCfbi08vzEZrTrBf_gQ1LyJXP_XsXocPdadDxMlpczbNm_rrb3yO__tXN-DaHJOSnaBEN2HFluuwsVPienx0TraIjxL12-_rcDkkrzzfgG_9k0k1woX1z-8__P0TxK7kBGe3aeVOA1x4K9EuU1FZjRRxRWQ0_BgU7hnpVNXYBtZxEu5WkLOhIp42Ylji1Iq1uvIzXy26ZTt2eYFIi6jSEHYLjnZf9jvdaJ7LIdLMnRKbWGnUBsozjSCTCoNQJFdZkbSMLmLNVdsWTOeCZ6nOcgfajEIwqduCUiOUobdhtaxKexdIGzUoLhRN2zpjqrC5UQk6aRxhVDwsasDjekzlOFB2yEDOnEiUrvTSbcCWH-3FG2py6mLcBJfHvT25l74b8PeMS9qAzVodJFqek5YqbTX7LNFXUsfg2IA7QUuWrQmaUCqwkad-rP_eDbnfeeMf7v37q5twpds_PJAHr3qv78PVOoAxbj2A1elkZh8iSprmj7wx_AIZVRAJ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFD4am0C8cNm4lNsshCZe0qWxHTfwNBW6MaCaYBMVQrIc22FlahKVdmKIB34Cv5FfwrHdtBoCCfEWWYntHJ9z_Nk-_g7AozQRCTdUR7k1KmJCoB-ksYksZ6KgTBfKZ2t4PUj3jtj-kA9X4GlzFybwQyw23JxleH_tDLw2xfaSNPSTrttuvSIuwBpLEfk6RPRmyR2VzfPI-xgEzjoNrVCcbC8-PTcZrTm5fvkT0jwPXP3M078KH5o-h4CTk_Zsmrf119_oHP_zp67BlTkiJTtBha7Dii3XYWOnxNX4-IxsER8j6jff1-FiSF15tgHfDo8n1RiX1T-___C3TxC5kmOc26aVOwtwwa1EuzxFZTVWxBWR8ehjULcnpFdVtQ2c4yTcrCCnI0U8acSoxIkVa3Xlp75adMq2dlmBSIeo0hB2A476zw97e9E8k0OkmTsjNrHSqAuUZxohJhUGgUiusiLpGF3EmquuLZjOBc9SneUOshmFUFJ3BaVGKENvwmpZlfY2kC7qT1womnZ1xlRhc6MSdNE4wKh2WNSCh82QyjoQdshAzZxIlK700m3Blh_sxRtqcuIi3ASX7wa7cjd9O-TvGZe0BZuNNki0OyctVdpq9lmip6SOv7EFt4KSLFsTNKFUYCOP_VD_vRtyv3fgH-78-6ubcOngWV--ejF4eRcuN9GLcecerE4nM3sfIdI0f-BN4RfsbA64 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Thrombin%E2%80%90mediated+hepatocellular+carcinoma+cell+migration%3A+Cooperative+action+via+proteinase%E2%80%90activated+receptors+1+and+4&rft.jtitle=Journal+of+cellular+physiology&rft.au=Kaufmann%2C+Roland&rft.au=Rahn%2C+Stephanie&rft.au=Pollrich%2C+Kristin&rft.au=Hertel%2C+Julia&rft.date=2007-06-01&rft.issn=0021-9541&rft.eissn=1097-4652&rft.volume=211&rft.issue=3&rft.spage=699&rft.epage=707&rft_id=info:doi/10.1002%2Fjcp.21027&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_jcp_21027 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9541&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9541&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9541&client=summon |